Mirae Asset Global Investments Co. Ltd. Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 33.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 278,234 shares of the medical research company’s stock after buying an additional 69,740 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $26,069,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EW. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Edwards Lifesciences by 98,836.3% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 759,315,387 shares of the medical research company’s stock worth $71,626,220,000 after purchasing an additional 758,547,908 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 3.8% in the 1st quarter. Wellington Management Group LLP now owns 15,850,055 shares of the medical research company’s stock valued at $1,311,275,000 after buying an additional 578,319 shares during the period. Moneta Group Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after buying an additional 15,384,593 shares during the period. Brown Advisory Inc. grew its holdings in Edwards Lifesciences by 1.6% in the 2nd quarter. Brown Advisory Inc. now owns 14,314,297 shares of the medical research company’s stock worth $1,350,268,000 after buying an additional 225,931 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Edwards Lifesciences by 0.6% during the 1st quarter. Geode Capital Management LLC now owns 12,214,619 shares of the medical research company’s stock worth $1,008,114,000 after acquiring an additional 78,376 shares during the period. Institutional investors own 79.25% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $77.79, for a total value of $564,366.45. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,497,301.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Larry L. Wood sold 8,660 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $65.30, for a total transaction of $565,498.00. Following the sale, the insider now directly owns 213,794 shares in the company, valued at $13,960,748.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $77.79, for a total value of $564,366.45. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,497,301.92. The disclosure for this sale can be found here. Insiders sold 179,795 shares of company stock worth $12,724,914 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. SVB Leerink initiated coverage on Edwards Lifesciences in a report on Monday, October 16th. They set a “market perform” rating and a $75.00 price target on the stock. Citigroup dropped their price target on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, October 26th. Truist Financial decreased their price objective on shares of Edwards Lifesciences from $83.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Oppenheimer upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, September 26th. Finally, Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $86.00 to $82.00 and set an “outperform” rating on the stock in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $84.29.

Edwards Lifesciences Trading Up 0.4 %

Shares of NYSE:EW opened at $67.19 on Tuesday. The company has a current ratio of 3.28, a quick ratio of 2.45 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $40.75 billion, a PE ratio of 28.71, a P/E/G ratio of 3.74 and a beta of 1.02. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $94.87. The firm has a fifty day moving average price of $68.93 and a 200 day moving average price of $79.38.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.59 EPS for the quarter, meeting analysts’ consensus estimates of $0.59. Edwards Lifesciences had a return on equity of 24.54% and a net margin of 24.59%. The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.48 billion. During the same quarter in the prior year, the firm posted $0.61 EPS. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.